ClinicalTrials.gg
CompletedNCT07640399Updated Jun 10, 2026

Stannous Fluoride Toothpaste for Reduction and Treatment of Gingivitis

An interventional study of Sodium Fluoride Dentifrice and Stannous Fluoride Toothpaste (SnF) in Gingival Inflammation, Plaque and Bleeding, sponsored by Church & Dwight Company, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Church & Dwight Company, Inc. · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Mar 2025, registered Jun 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing Tin Fluorides in Gingivitis — 1 open to participants now, 3 under way, none of them phase 3. Tin Fluorides · Gingivitis.

Enrollment
7th of 23
133 · median 115
Started
2025
with 2 others
No phase
10 of 23
none open now
Registered
22nd of 23
by date
Lead sponsor
1 of 23
Church & Dwight Company, Inc.

Among the 23 studies testing Tin Fluorides in Gingivitis, this one is the 7th largest by enrollment, is one of 3 that started in 2025, is one of 10 with no phase, and was the 22nd registered.

Gingivitis

631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

Browse Gingivitis studies →

Open to participants now

1 of the 23 studies testing Tin Fluorides in Gingivitis is open now. Recruiting first, the newest first:

About Tin Fluorides

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 53 Gingivitis studies recruiting now, 15 (28%) set no upper age limit and 36 (68%) stop at 75 or younger; 11 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing Tin Fluorides in Gingivitis, or all of them as a file.
02

Study summary

This study evaluated the efficacy of a stannous fluoride toothpaste compared to a sodium fluoride control toothpaste in reducing gingivitis, bleeding, and plaque over a 12-week period.

A total of 132 subjects were randomized to one of two treatment groups and assessed at baseline and at Weeks 2, 4, 8, and 12 using standardized clinical indices, including the Modified Gingival Index (MGI), Bleeding Index (BI), and Plaque Index (PI).

03

Conditions studied

  • Gingival Inflammation
  • Plaque
  • Bleeding
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 18 to 65 years (inclusive)
  • Provided written prior to participation
  • Able to brush their own teeth on a daily basis
  • In good general health based on medical history review
  • Minimum of at least 18 natural, scorable teeth
  • Mean plaque index score ≥ 1.95
  • Mean baseline gingival index score ≥ 1.70 and ≤ 3.0
  • Agreed to refrain from use of all oral hygiene products other than those supplied for the study
  • Agreed to refrain from oral hygiene, eating, drinking, and chewing gum for approximately 12 hours prior to study visits
  • Agreed not to undergo dental prophylaxis or elective dental procedures during the study
  • Willing and able to comply with study procedures and visit schedule

Exclusion criteria

Exclusion Criteria:

  • Physical limitations or restrictions that preclude normal tooth brushing
  • Requirement for premedication prior to dental treatment
  • Pregnancy or intent to become pregnant during the study period
  • Use of tobacco or nicotine products
  • Poor oral hygiene defined as >40 bleeding sites
  • Presence of dental caries or calculus deposits that may interfere with plaque assessments
  • Major oral hard or soft tissue lesions or trauma at baseline
  • Presence of fixed or removable orthodontic appliances
  • Dental prophylaxis within 1 month prior to baseline visit
  • History of significant adverse events, allergy, or irritation related to oral hygiene products
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
133 participants (actual)

Study arms

  • Active comparator
    Sodium Fluoride Control Dentifrice

    Dentifrice containing sodium fluoride, serving as the control comparator

    Drug: Sodium Fluoride Dentifrice

  • Experimental
    Stannous Fluoride Toothpaste

    Dentifrice containing stannous fluoride evaluated for gingivitis effect

    Drug: Stannous Fluoride Toothpaste (SnF)

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the efficacy of a stannous fluoride toothpaste in gingival inflammation

    Change from baseline in whole-mouth Modified Gingival Index (MGI) score at Week 12 Whole-mouth gingival inflammation will be assessed using the Modified Gingival Index (MGI). Scores are recorded on scorable gingival areas of all scorable teeth using a 0-4 scale, and the whole-mouth MGI score is calculated as the sum of all site scores divided by the number of scorable sites examined. The primary analysis compares the change from baseline to Week 12 between treatment groups.

    Time frame: 12 weeks

Secondary outcomes

  1. Evaluate improvements at weeks 2, 4, 8; assess gingival bleeding at weeks 2, 4, 8, and 12 weeks

    Secondary outcome measures include change from baseline in whole-mouth bleeding index at Weeks 2, 4, 8, and 12...based on scorable gingival areas using the Saxton 0-2 scale

    Time frame: 2, 4, 8, and 12 weeks

  2. Evaluate improvements at weeks 2, 4, 8; assess plaque control at weeks 2, 4, 8, and 12 weeks

    Secondary outcome measures include change from baseline in plaque at Weeks 2, 4, 8, and 12...calculated from disclosed plaque scores on scorable buccal and lingual tooth surfaces using the Soparkar Modification of the Turesky Modification of the Quigley-Hein Plaque Index; lower scores indicate improvement for all measures.

    Time frame: 2, 4, 8, and 12 weeks

  3. Evaluate improvements at weeks 2, 4, 8; in whole mouth Modified Gingival Index (MGI) scores

    Secondary outcome measures include change from baseline in whole-mouth MGI at Weeks 2, 4, and 8, using the Modified Gingival Index (MGI). Scores are recorded on scorable gingival areas of all scorable teeth using a 0-4 scale, and the whole-mouth MGI score is calculated as the sum of all site scores divided by the number of scorable sites examined.

    Time frame: 2, 4, and 8 weeks

07

Study locations

1 site
  • All Sum
    Mississauga, Ontario L5N 6J2, Canada
08

References and documents

Individual participant data

Plan to share: No — The sponsor does not plan to share individual participant data. Summary results will be provided as required, but no de identified datasets will be made publicly available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Jun 2025, 2 months.

Of 53 industry-sponsored interventional studies with no phase under Gingivitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 5. This study's 2 months is below that.

Counting every sponsor, half of 257 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 10, 2026
StartActual
Mar 17, 2025
Primary completionActual
Jun 13, 2025
CompletionActual
Jun 13, 2025
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07640399
Responsible party
Sponsor
First posted
Jun 10, 2026
Start date
Mar 17, 2025
Primary completion
Jun 13, 2025
Completion
Jun 13, 2025
Last update
Jun 10, 2026

Study contacts

Annahita Ghassemi
study director · Church & Dwight, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tin Fluorides

Start the discussion